Biased T Cell Receptor Usage Directed against Human Leukocyte Antigen DQ8-Restricted Gliadin Peptides Is Associated with Celiac Disease
Sophie E Broughton, Jan Petersen, Alex Theodossis, Stephen W Scally, Khai Lee Loh, Allan Thompson, Jeroen van Bergen, Yvonne Kooy-Winkelaar, Kate N Henderson, Travis Beddoe, Jason A Tye-Din, Stuart I Mannering, Anthony W Purcell, James McCluskey, Robert P Anderson, Frits Koning, Hugh H Reid, Jamie Rossjohn
Immunity | CELL PRESS | Published : 2012
Awarded by NHMRC Independent Research Institutes Infrastructure Support Scheme
Awarded by Dutch government
This work was supported by the National Health and Medical Research Council, the Australian Research Council, an NHMRC Independent Research Institutes Infrastructure Support Scheme grant #361646, Victorian State Government Operational Infrastructure Support, the Celiac Disease Consortium, an Innovative Cluster approved by The Netherlands Genomics Initiative, and the Dutch government (grant BSIK03009). We thank the staff at the MX1 beamline of the Australian Synchrotron, Victoria, Australia for assistance with data collection. We thank J. Dromey for assistance. T.B. is supported by Pfizer Australian Research fellowship; J.A.T.-D. is supported by a NHMRC Australian Research Training Fellowship; S.E.B. is supported by an NHMRC PhD scholarship; A.W.P. is supported by an NHMRC SRF; and J.R. is supported by an Australia Fellowship from the NHMRC. J.A.T.-D. and R.P.A. are coinventors of patents pertaining to the use of gluten peptides in therapeutics, diagnostics, and nontoxic gluten. R.P.A. and J.A.T.-D. are shareholders in Nexpep Pty Ltd and R.P.A. is a shareholder in ImmusanT Inc. R.P.A. is Chief Scientific Officer of and J.A.T.-D. is a consultant to ImmusanT, Inc., a company developing a peptide-based therapy and diagnostic suitable for celiac disease.